RESUMEN
(1) Background: This study aimed to determine the relationship between metabolic urine conditions and the formation, severity, and composition of encrustations in ureteral stents. (2) Methods: Ninety stone-former patients requiring a double-J stent were prospectively enrolled. We collected 24 h metabolic urine samples and demographic data, including indwelling time and previous stone composition. The total deposit weight was obtained, and a macroscopic classification according to the degree of encrustation (null, low, moderate, and high) was created, allowing for intergroup comparisons. Stereoscopic and scanning electron microscopy were performed to identify the type of embedded deposits (calcium oxalate, uric acid, and infectious and non-infectious phosphates). (3) Results: In total, 70% of stents were encrusted; thereof, 42% had a moderate degree of encrustation. The most common encrustation type was calcium oxalate, but infectious phosphates were predominant in the high-encrustation group (p < 0.05). A direct correlation was observed between the purpose-built macroscopic classification and the encrustation weights (p < 0.001). Greater calciuria, uricosuria, indwelling time, and decreased diuresis were observed in stents with a higher degree of encrustation (p < 0.05). The urinary pH values were lower in patients with uric acid encrustations and higher in those with infectious phosphate encrustations (p < 0.05). When compared to non-encrusted stents, patients with calcium-oxalate-encrusted stent showed greater calciuria, phosphaturia, indwelling time, and reduced diuresis; patients with uric-acid-encrusted stent showed greater uricosuria; and patients with infectious and non-infectious phosphate encrustation showed greater urinary pH (p < 0.05). (4) Conclusions: Metabolic urine conditions play a critical role in the formation, composition, and severity of double-J stent encrustation.
RESUMEN
PURPOSE: Female representation at scientific conferences is crucial for encouraging women pursuing an academic career. Nevertheless, gender inequity at urological conferences is common place and women are often stereotyped choosing functional urology. However, there is no evidence whether female representation is higher in functional urology. This investigations aims to analyze gender representation at functional urology sessions. METHODS: National and international urological congresses between 2019 and 2021 with a focus on functional urology and female urology sessions were evaluated. Congresses were categorized as national or international. Session type, topic, gender of chairs and speakers of the identified sessions were recorded. In addition, affiliation and medical specialty were collected for chairs. RESULTS: A total of 29 congresses were evaluated. Out of a total of 2893 chairs and speakers, 1034 (35.7%) were women and 1839 (63.6%) were men. This represents an overall gender gap of 27.9% for functional urology sessions. No significant differences in gender representation between national and international congresses could be identified (p = 0.076). When considering gender distribution of chairs, the gap was more pronounced by 35.5%. Furthermore, men were more likely to be invited to be a speaker in plenary and podiums sessions. CONCLUSIONS: Gender inequality is present in functional urology sessions. There is a need for greater efforts to achieve gender equality. An important step to remedy the situation is the inclusion of women in scientific program committees. Furthermore, support by the leadership of urological societies and academic departments is essential to herald a lasting change in gender inequality.
Asunto(s)
Médicos Mujeres , Urología , Masculino , Humanos , Femenino , Urólogos , Sociedades Médicas , OrganizacionesRESUMEN
INTRODUCTION: Urological cancers can be challenging in the diagnosis and treatment of patients with neurological diseases. As a result, there are still uncertainties regarding the incidence and risk factors favouring the development of urological cancers in these patients. The aim of this study was to review the available evidence regarding the incidence for the development of urological cancers in neurological patients to provide a basis for future recommendations and research. EVIDENCE ACQUISITION: A narrative review of the literature in Medline and Scopus up to June 2019 was performed. EVIDENCE SYNTHESIS: After screening 1729 records, 30 retrospective studies were retained. For bladder cancer (BC), 21 articles were identified, including a total of 673,663 patients. Among these patients, 4744 had a diagnosis of BC (1265 females, 3214 males, gender not reported in 265). In this group, 2514 were diagnosed with BC associated with a neurological disease. For prostate cancer (PC), 14 articles were identified, including a total of 831,889 men. Among these patients, 67,543 had a diagnosis of PC and 1457 had PC and a neurological disease. Two articles reported kidney cancer (KC), one reported testicular cancer (TC) and none described penile cancer or urothelial carcinomas of the upper urinary tract in neurological patients. CONCLUSIONS: The incidence of urological cancers, especially BC and PC, in patients with neurological diseases appears comparable to the general population. However due to the paucity of studies, specific recommendations for the management are lacking in neurologically disabled patients. In this report we investigated the frequency of urinary tract cancers in patients with neurological diseases. We conclude that urological cancers, especially bladder and prostate cancer, in patients with neurological diseases occur with similar frequency as in the general population.
Asunto(s)
Neoplasias Renales , Enfermedades del Sistema Nervioso , Neoplasias de la Próstata , Neoplasias Testiculares , Neoplasias de la Vejiga Urinaria , Neoplasias Urológicas , Masculino , Humanos , Urólogos , Incidencia , Estudios Retrospectivos , Neoplasias Urológicas/diagnóstico , Neoplasias Urológicas/epidemiología , Neoplasias Renales/diagnóstico , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/epidemiología , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/epidemiologíaRESUMEN
PURPOSE: Continence assessment is an essential component of follow-up after radical prostatectomy (RP). Several methods exist to assess the severity of urinary incontinence (UI). Our study examined the relationship and degree of agreement between International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) scores and the number of pads used in a 24-hour period in the assessment of UI following RP. METHODS: Continence was prospectively assessed in 746 men from a Spanish urology clinic 12 months after RP using the ICIQ-SF and pad usage. The relationship between ICIQ-SF scores and pad usage was assessed using Spearman rank correlation coefficients. The Jonckheere-Terpstra trend test was used to determine whether the ICIQ-SF score and the component question scores increased with increasing pad usage. The Bonferroni-corrected pairwise Wilcoxon rank-sum test was used to determine which pairs of pad usage levels differed. The weighted kappa was used to evaluate the agreement between pad usage levels and ICIQ-SF questions. RESULTS: The continence rate was 82% using the "no pad usage" definition of continence versus 78% using the definition of an ICIQ-SF score of 0 (P<0.001). Strong positive correlations were observed between the number of pads and the ICIQ-SF total and component question scores (rs>0.85, P<0.001). The ICIQ-SF total and component question scores increased significantly with increasing pad usage (P<0.001). The ICIQ-SF scores (P<0.018) for all pairs of pad usage levels (0, 1, 2, or 3 or more) differed significantly. The agreement between the ICIQ-SF leakage amount question and pad usage was very good (rs=0.861, P<0.001). CONCLUSION: At 12 months post-RP, 24-hour pad usage was closely correlated with ICIQ-SF, although the continence rate differed depending on the definition used. Higher levels of pad usage were associated with higher questionnaire scores, more leakage, and poor quality of life (interference with everyday life).
RESUMEN
BACKGROUND: We aimed to study the continence between intermediate and high-risk cancer patients and the influential factors to recover continence. MATERIALS AND METHODS: In total, 655 patients underwent surgery by robot-assisted radical prostatectomy between 2010 and 2015. Of 655 patients, 294 were classified according to D'Amico risk groups as intermediate risk or high risk and completed the micturition protocol. Patients with intermediate risk were matched in a 1:1 ratio to patients with high risk for age and body mass index. Urine loss ratio (ULR) was defined as urine loss divided by micturition volumes. Immediate continence was defined with the best cut-off value of ULR. RESULTS: In total, 117 patients with intermediate risk were matched to those with high risk. The comparison did not show any statistically significant difference in the ULR value (P = 0.359) or continence rate (P = 0.449). Predictive analysis was performed for the 294 patients (intermediate and high risk), of which 9.5% were classified as incontinent (>1 pad/d). Immediate continence was defined as ULR < 0.049 in 232 (78.9%) patients. Age, preoperative hemoglobin, and duration of catheterization were found influent by univariate analysis. Only age [odds ratio (OR) = 1.072; 95% confidence interval (CI) = 1.020-1.127; P = 0.006] and duration of catheterization (OR = 1.060; 95% CI = 1.003-1.120; P = 0.040) were independent influential factors to predict immediate continence. CONCLUSION: D'Amico intermediate- and high-risk groups do not differ in continence terms. The ULR value of < 0.049 identifies those patients who recover continence earlier. Age and duration of catheterization were influential factors in predicting immediate continence.
RESUMEN
Pigmented microcystic chromophobe renal cell carcinoma (PMChRCC) is a recently described morphologic variant of ChRCC. We have identified 42 cases in 40 patients in the last 24 years. We have investigated their clinical, morphologic, immunohistochemical, and cytogenetic features. Chromosomal abnormalities of chromosomes 7 and 17 were evaluated by automated dual-color silver-enhanced in situ hybridization on paraffin-embedded tissue. Chromosomal imbalance was defined on the basis of changes in both chromosomal index and signal distribution. The main age was 60.20 years, being 34 males and 6 women. The mean tumor diameter was 4.84 cm, with 39 intrarenal tumors. Grossly, the tumors were solid with a brown dark colored. Microscopically, tumors consisted of pale and eosinophilic cells arranged in microcysts or microalveolar in a cribriform pattern; there were microcalcifications and a dark brown pigment, mostly extracellular. One case showed sarcomatoid transformation. All tumors were positive for epithelial membrane antigen (EMA), Claudin 7, and E-cadherin. Monosomy of 7 and 17 chromosomes was present in 1/36 cases and 2/37 cases, respectively. Polysomy of chromosome 7 and 17 was found in 26/36 cases and in 4/37, respectively. With a median follow-up of 74.05 months, 37 patients were alive without disease and two were alive with disease progression. PMChRCCs expand the morphologic spectrum of the ChRCC with an unusual immunohistochemical profile. Cytogenetically, they showed monosomy to chromosome (CHR) 17 as other ChRCCs and polysomy of CHR 7 infrequent to ChRCCs. We present the probably largest series of PMCRCC, confirming their low aggressive behavior, with exceptional sarcomatoid transformation and distant metastases.
Asunto(s)
Biomarcadores de Tumor , Carcinoma de Células Renales/química , Carcinoma de Células Renales/genética , Inmunohistoquímica , Hibridación in Situ , Neoplasias Renales/química , Neoplasias Renales/genética , Neoplasias Quísticas, Mucinosas y Serosas/química , Neoplasias Quísticas, Mucinosas y Serosas/genética , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/genética , Carcinoma de Células Renales/mortalidad , Carcinoma de Células Renales/terapia , Cromosomas Humanos Par 17 , Cromosomas Humanos Par 7 , Diagnóstico Diferencial , Femenino , Predisposición Genética a la Enfermedad , Humanos , Neoplasias Renales/mortalidad , Neoplasias Renales/terapia , Masculino , Persona de Mediana Edad , Neoplasias Quísticas, Mucinosas y Serosas/mortalidad , Neoplasias Quísticas, Mucinosas y Serosas/terapia , Fenotipo , Ploidias , Valor Predictivo de las Pruebas , España , Factores de Tiempo , Resultado del TratamientoRESUMEN
AIMS: To assess prevalence of urinary incontinence (UI) after radical prostatectomy (RP) and to analyze which preoperative characteristics of the patients have influence on UI. METHODS: Between 2002 and 2012, 746 consecutive patients underwent RP for clinically localized prostate cancer. We defined UI according to International Continence Society (ICS) definition: "the complaint of any involuntary leakage of urine" after 12 months of recovery, international consultation on incontinence questionnaire (ICIQ-SF) and pads/day was collected too. Clinical features and magnetic resonance imaging measurements were assessed. A multivariable logistic regression model predicting incontinence were built-in after adjust by cofounding factors and bootstrapping. RESULTS: About 172 (23%) of the patients were classified as incontinent according to the ICS definition. The mean value of the ICIQ-SF was 10.87 (±4). 17.8% of patients use at least one pad/day, 11.9% use more than one pad/day. The preoperative factors independently influential in UI are: age [OR: 1.055; CI 95% (1.006-1.107), p = .028], urethral wall thickness [OR: 5.03; CI 95% (1.11-22.8), p = .036], history of transurethral resection of the prostate [OR: 6.13; CI 95% (1.86-20.18), p = .003] and membranous urethral length [OR: 0.173; CI 95% (0.046-0.64), p = .009]. The predictive accuracy of the model is 78.7% and the area under the curve (AUC) value 71.7%. CONCLUSIONS: Urinary incontinence after radical prostatectomy has different prevalence depending on the definition. Age, prior transurethral resection of the prostate (TURP), membranous urethral length (MUL) and urethral wall thickness (UWT) were risk factors.
Asunto(s)
Complicaciones Posoperatorias/epidemiología , Prostatectomía/efectos adversos , Neoplasias de la Próstata/cirugía , Incontinencia Urinaria/epidemiología , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Humanos , Modelos Logísticos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Prevalencia , Próstata/diagnóstico por imagen , Próstata/patología , Estudios Retrospectivos , Factores de Riesgo , Encuestas y Cuestionarios , Resección Transuretral de la Próstata/efectos adversos , Uretra/diagnóstico por imagen , Uretra/patologíaRESUMEN
BACKGROUND: The aim of this study was to analyze what kind of urinary symptoms patients have before receiving treatment by radical prostatectomy (RP), and to evaluate their influence on urinary incontinence (UI). METHODS: Between 2002 and 2012, 758 consecutive patients underwent RP for clinically localized prostate cancer (PCa). Surgery was carried out by open retropubic RP in 545 (73.1%) of patients and laparoscopic RP in 201 (27%) by 5 surgeons who were excluded from data collection and analysis. The following symptoms were collected from the last urological check-ups or pre-operative consultation and classified as: storage symptoms, voiding symptoms, post micturition symptoms, history of acute urinary retention, benign prostatic hyperplasia treatment, history of transurethral resection of the prostate (TURP). RESULTS: A total of 661 patients were included on analysis: 136 (20.6%) patients reported low urinary tract symptoms (LUTS), 162 (24.5%) were considered incontinent after RP, and 45 (33.1%) of them reported LUTS before surgery. Postprostatectomy urinary incontinence (PPUI) was significantly different in patients with LUTS (117 [22.3%] vs. 45 [33.1%], P=0.009). The presence of any LUTS influence significantly in the appearance of PPUI (OR=1.72 [95% CI: 1.14-2.6), P=0.01). TURP is independently influential in PPUI (OR=6.13 [95% CI: 1.86-20.18], P=0.003). A patient with LUTS before surgery has an increased risk of 70% or even 200% to suffer PPUI and a patient who received treatment by TURP is 6 times at higher risk of PPUI. CONCLUSIONS: In conclusion, patients with LUTS are likely to present PPUI. History of TURP is influential by itself over PPUI. A good preoperative consultation is important to assess continence status and to create realistic expectations to patients before RP.
Asunto(s)
Síntomas del Sistema Urinario Inferior/complicaciones , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Resección Transuretral de la Próstata/efectos adversos , Incontinencia Urinaria/epidemiología , Incontinencia Urinaria/etiología , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Próstata/cirugíaRESUMEN
OBJECTIVES: Prostate cancer can be treated by radical prostatectomy and provoke urinary incontinence as secondary effect. Our aim is to calculate the prevalence of urinary incontinence, characteristics of leakage and influential factors, through a historical series. METHODS: We perform a descriptive, observational and retrospective study of 1310 patients who received treatment for PCa between 1989 and 2011. Prevalence was obtained after 12 months of recovery and using ICS definition. To complete ICIQ-SF and number of pads/day used we perform a cross-sectional study. The series is studied globally and divided in two groups according to oncologic characteristics. We perform a descriptive, comparative and predictive analysis. RESULTS: Prevalence of the series was 23.5%, 296 patients. 279 incontinent patients completed ICIQ-SF with a mean score of 11.1±4.03. 16.4% of the patients use 1 pad/day or none, 69% (11.4% of the total) use compress and 22% diapers. 8% of the total use more than 1 pad/day. Clinico-pathological factors divide series in two groups: 1989-1999 with a prevalence of 24.6% and 2000-2011 with 22.8%. Multivariate analysis shows influential factors: age (65 years) (OR:1.65, p=0.013) and prostate volume (50cc) (OR:1.49, p=0.029). CONCLUSIONS: Urinary incontinence is a disease with some prevalence that varies depending on definition. The most common situation was to leak several times a day (42.2%), a small amount (59.1%), using compress (69%) most of incontinents with a mild (0-7: 88.2%) impact on quality of life. Predictive factors were age (65 years) and prostate volume (50cc). The historical changes does not influence over prevalence.
Asunto(s)
Prostatectomía/efectos adversos , Incontinencia Urinaria/diagnóstico , Incontinencia Urinaria/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Incontinencia Urinaria/etiologíaRESUMEN
OBJETIVO: El tratamiento del cáncer de próstata mediante prostatectomía radical puede ocasionar incontinencia urinaria. Nuestro objetivo es calcular la prevalencia de incontinencia urinaria a través del análisis de una serie histórica, analizar las características de las pérdidas y los factores influyentes en la aparición de incontinencia. MÉTODOS: Estudio descriptivo, observacional y retrospectivo de las variables clinicopatológicas de 1310 pacientes intervenidos entre 1989-2011. La prevalencia se calcula a los 12 meses de la cirugía usando la definición de ICS. Estudio transversal para completar el cuestionario ICIQ-SF y las protecciones usadas. Se estudia la serie completa y en dos grupos según características oncológicas. Se realiza estudio descriptivo, comparativo y predictivo. RESULTADOS: La prevalencia de la serie es de 23.5% con 296 pacientes. 279 incontinentes completaron el cuestionario ICIQ-SF con una media de 11.1±4.03. 16.4% de los pacientes intervenidos usan al menos 1 protección al día, de ellos el 69% usan compresas (11.4% del total), y el 22% pañales clásicos. El 8% usa más de una protección al día. Las características clinicopatológicas dividen la serie en dos grupos distintos: 1989-1999 con una prevalencia de 24.6% y grupo 2000-2011 con 22.8%. El análisis multivariado encontramos la edad (65 años) (OR:1.65, p = 0.013) y volumen prostático (50cc) (OR:1.49, p = 0.029) influyentes de forma independiente. CONCLUSIONES: La incontinencia urinaria es una enfermedad de cierta prevalencia, que varía según la definición que utilicemos. La situación más frecuente en los pacientes incontinentes es tener pérdidas varias veces al día (42.2%), poca cantidad (59.1%), usando protecciones tipo compresa (69%) y afectando la calidad de vida de forma leve-moderada (0-7: 88.2%). Las variables predictivas fueron la edad (65 años) y el volumen prostático (50cc). La evolución histórica de los pacientes no influye en la prevalencia de incontinencia urinaria
OBJECTIVES: Prostate cancer can be treated by radical prostatectomy and provoke urinary incontinence as secondary effect. Our aim is to calculate the prevalence of urinary incontinence, characteristics of leakage and influential factors, through a historical series. METHODS: We perform a descriptive, observational and retrospective study of 1310 patients who received treatment for PCa between 1989 and 2011. Prevalence was obtained after 12 months of recovery and using ICS definition. To complete ICIQ-SF and number of pads/day used we perform a cross-sectional study. The series is studied globally and divided in two groups according to oncologic characteristics. We perform a descriptive, comparative and predictive analysis. RESULTS: Prevalence of the series was 23.5%, 296 patients. 279 incontinent patients completed ICIQ-SF with a mean score of 11.1±4.03. 16.4% of the patients use 1 pad/day or none, 69% (11.4% of the total) use compress and 22% diapers. 8% of the total use more than 1 pad/day. Clinico-pathological factors divide series in two groups: 1989-1999 with a prevalence of 24.6% and 2000-2011 with 22.8%. Multivariate analysis shows influential factors: age (65 years) (OR:1.65, p = 0.013) and prostate volume (50cc) (OR:1.49, p = 0.029). Concluisions: Urinary incontinence is a disease with some prevalence that varies depending on definition. The most common situation was to leak several times a day (42.2%), a small amount (59.1%), using compress (69%) most of incontinents with a mild (0-7: 88.2%) impact on quality of life. Predictive factors were age (65 years) and prostate volume (50cc). The historical changes does not influence over prevalence
Asunto(s)
Humanos , Masculino , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , Incontinencia Urinaria/metabolismo , Incontinencia Urinaria/patología , Pañales para Adultos/normas , Prostatectomía/métodos , Epidemiología Descriptiva , Estudios Retrospectivos , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/radioterapia , Incontinencia Urinaria/complicaciones , Incontinencia Urinaria/diagnóstico , Pañales para Adultos , Prostatectomía/instrumentación , Estudio ObservacionalRESUMEN
PURPOSE: Prostate cancer can be treated by radical prostatectomy (RP) and provoke a troublesome side effect: urinary incontinence (UI). We propose a verification of the usefulness of MRI and an identification of which structures are involved in UI after RP. METHODS: Between September 2002 and December 2011, 550 patients underwent RP. We performed MRI to evaluate extraprostatic disease before surgery. To evaluate patient status, we measured the following structures: length (LP), width (WP), height (HP) and volume (PV) of the prostate, membranous urethral length (MUL), urethral wall thickness (UWT), levator ani muscle (LAM) and obturator internus muscle (OIM) thickness, ratio of levator ani muscle/prostate volume (LAM/PV), volume of the urethra (VU). UI was defined according to ICS definition as the complaint of any involuntary leakage of urine and evaluated 1 year after surgery. Analyses were performed by mean comparisons, univariate and multivariate logistic regression with a 1000-resample bootstrapping. RESULTS: Means of measurements were: LP 4.46 cm, WP 5.15 cm, HP 3.9 cm, PV 49.3 cc; LAM 0.51 cm, OIM 1.46 cm; MUL 1.43 cm, UWT 1.38 cm; and LAM/PV 0.013 cm/cc, VU 2.33 cc. One hundred and twenty-two (22.2 %) patients complained of urine leakage. Univariate obtained differences in PV, OIM, MUL, and UWT. After adjusting by confounders, multivariate analysis showed: MUL: [OR 0.134; CI 95 % (0.022-0.493); P 0.006]; PV: [OR 1.016; CI 95 % (1.004-1.029); P 0.005]; UWT: [OR 6.03; CI 95 % (1.068-44.1); P 0.033]. CONCLUSIONS: MRI is a useful tool to predict UI after RP. The MUL and PV are well-identified structures that are involved in UI. Our study shows that UWT also influences UI.
Asunto(s)
Laparoscopía , Imagen por Resonancia Magnética/métodos , Diafragma Pélvico/patología , Complicaciones Posoperatorias/diagnóstico , Prostatectomía/métodos , Neoplasias de la Próstata/cirugía , Incontinencia Urinaria/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Valor Predictivo de las Pruebas , Próstata/patología , Prostatectomía/efectos adversos , Estudios Retrospectivos , Incontinencia Urinaria/etiologíaRESUMEN
INTRODUCTION: We evaluate the prognosis of patients with biochemical recurrence (BCR) treated with androgen deprivation therapy (ADT) and to determine the influential factors to castration resistance (CR) and death. METHODS: From a series of 1310 patients with T1-T2 prostate cancer treated with radical prostatectomy between 1989 and 2012, 371 had BCR. Patients with lymph node involvement were excluded. We analyzed only the 159 treated with salvage ADT. At the end of the study, 77 (48%) had developed CR. RESULTS: The median follow-up to CR was 9.2 years. The CR-resistant free survival (RFS) was 76 ± 3%, 62 ± 3% and 43 ± 9% in 5, 10 and 15 years, respectively. The RFS median time was 14 years. In the multivariate study, the prostate-specific antigen (PSA) doubling time (PSA-DT) was <6 months (p = 0.01) (hazard ratio [HR] 3; 95% confidence interval [CI] 1.4-6.8, p = 0.007); seminal vesicle involvement (HR 3.1; 95% CI 1.5-6.2, p = 0.01) and PSA velocity in ng/mL/year (HR 1.3; 95% CI 1.1-1.5, p = 0.002) with better cut-off points of 0.84 ng/mL/year (p = 0.04) (HR 4; 95% CI 1.7-9.4, p = 0.001) were influential variables. Specific survival (SS) at 5, 10 and 15 years since surgery was 96 ± 1, 85 ± 2 and 76 ± 4, respectively. The time of CR to death was 30 ± 6% at 5 years, with the median at 3.2 years. In the multivariate only Ki 67 (HR 1.04; 95% CI 1.005-1.08, p = 0.02) had an independent influence. CONCLUSIONS: In BCR patients treated with ADT, the median to CR was 14 years. PSA-DT <6 months, PSA velocity (ng/mL/year) and seminal vesicle involvement were influential variables. From the CR, the median time to death was 3.2 years. Ki-67 marker was an independent influence.
RESUMEN
Emphysematous pyelonephritis is an acute necrotizing infection with gas in the kidney and perinephric space that carries a bad prognosis. Apart from its predisposing clinical entities, diabetes mellitus and immune-incompetence are quite common in patients with this infection. We report a case of a 53-year-old kidney transplant recipient diabetic male, suffering from recurrent fever, abdominal pain and nausea episodes. Immediate broad-spectrum antibiotics were administered and percutaneous drainage was performed after the diagnosis. The bacteria involved were Stahpylococcus epidermidis and Escherichia coli. After 4 weeks of antibiotic treatment and abscesses drainage, the case was resolved. Consecutives urine cultures and ultrasonographies confirm the complete resolution of the disease. We discuss the predisposing factors, clinical presentation and management.
RESUMEN
OBJECTIVES: We intend to analyze the prognostic value of positive surgical margins depending on their number and location in pT2 patients. METHODS: We analyze 448 (34.3%) patients with positive surgical margins from a series of 1,310 T1-T2 patients treated with radical prostatectomy between 1989-2012. Of them 164 are pT2 (+). 119 (72.6% ) have unifocal affectation (41 (34.5%) unifocal in right lobe; 35 (29.4%) unifocal in left lobe, 40 (33.6%) unifocal in apex, 3 (2.5% ) unifocal proximal) and 45 (27.4%) multifocal involvement. RESULTS: Unifocal and multifocal pT2(+)patients have not evidenced significant differences in any of the clinicopathologic variables compared. However the BPFS at 5 and 10 years is significantly worse in the multifocal group, (p<0.000) In the BPFS multivariate study of 164 pT2(+ )influential variables are: multifocal involvement (HR: 3.4; 95%IC 1.7-6.9 p<0.000) and PSA (HR: 1.03; 95%IC 1.02-1.05 p<0.000), being PSA >15 ng/ml )HR: 3.7; 95%IC 2.1-6.6 p<0.000 ( the best cut-off point. Risk groups: Using the independent influence variables, the best model (using Cox models ) includes two risk groups: Group 1 (0 variables): They are pT2(+) with unifocal affectation and PSA<15 ng/ml, (63%). Their BPFS are 81±4% and 77±4% (5 and 10 years). Grupo 2 (1-2 variables): They are pT2 (+) with multifocal involvement, PSA> 15 ng/ml or both of them, (37%). Their BPFS are 46±6% and 26±7% (5 and 10 years). The BPFS differs significantly between the two groups (p<0.000). The Group 1 BPFS is similar to the pT2 (-) patients, (p:0.242). The Group 2 BPFS is similar to the pT3(+) patients, (p:0.637). The model explained significantly better the BPFS than any of the individual variables analyzed. CONCLUSIONS: In pT2(+) patients the prognosis is significantly worse in multifocal involvement. In addition two groups of patients can be clearly distinguished from the BPFS point view according to their influential variables. The data suggest that since the prognostic point view the second group is understaged while the first is overstaged.
Asunto(s)
Adenocarcinoma/cirugía , Estadificación de Neoplasias , Prostatectomía/métodos , Neoplasias de la Próstata/cirugía , Adenocarcinoma/sangre , Adenocarcinoma/patología , Anciano , Supervivencia sin Enfermedad , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Residual , Pronóstico , Modelos de Riesgos Proporcionales , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/patología , Estudios RetrospectivosRESUMEN
OBJETIVO: Pretendemos analizar en los pacientes pT2 con márgenes afectados el valor pronóstico real de los márgenes en función de su número y localización. MÉTODOS: Analizamos 448 (34,3%) pacientes con márgenes afectados de una serie de 1.310 pacientes T1-T2 tratados mediante prostatectomía radical entre 1.989-2.012. De ellos 164 son pT2(+), 119 (72,6%) tienen afectación unifocal 41 (34,5%) unifocal en lóbulo derecho; 35 (29,4%) unifocal en lóbulo izquierdo, 40 (33,6%) unifocal en ápex, 3 (2,5%) unifocal proximal) y 45 (27,4%) afectación multifocal. RESULTADOS: Los pT2(+) unifocales y multifocales no evidencian diferencias significativas en ninguna de las variables clínico-patológicas comparadas. Sin embargo la Supervivencia Libre de Progresión Bioquímica (SLPB) a 5 y 10 años es significativamente peor en el grupo multifocal, (p<0,000). En el estudio multivariado son influyentes en la SLPB de los 164 pT2(+): afectación multifocal (HR: 3,4; IC 95% 1,7-6,9 p<0,000) y PSA (HR: 1,03; IC 95% 1,02-1,05 p<0,000) siendo el mejor punto de corte, PSA >15 ng/ml (HR: 3,7; IC 95% 2,1-6,6 p<0,000). Grupos de Riesgo: Utilizando las variables de influencia independiente el mejor modelo utilizando los modelos de Cox incluye dos grupos de riesgo: Grupo 1 (0 variables presentes): Son pT2(+) con afectación unifocal y PSA<15 ng/ml, (63%). Su SLPB es 81±4% y 77±4% (5 y 10 años). Grupo 2 (1-2 variables presentes): Son pT2(+) con afectación multifocal, PSA>15 ng/ml o ambas, (37% restante). Su SLPB es 46±6% y 26±7% (5 y 10 años). La SLPB es significativamente diferente entre ambos grupos (p<0,000). La SLPB del Grupo 1 es similar a la de los pacientes pT2 márgenes (-), (p=0,242). La SLPB del Grupo 2 es similar a la de los pT3 márgenes (+), (p=0,637). El modelo explica significativamente mejor la SLPB que cualquiera de las variables analizadas individualmente (estudio multivariado, modelo de Cox). CONCLUSIONES: En los pT2(+) el pronóstico es significativamente peor cuando la afectación es multifocal. Además pueden diferenciarse claramente dos grupos de pacientes desde el punto de vista de la SLPB según sus variables influyentes. Los datos sugieren que desde el punto de vista del pronóstico el segundo grupo está infraestadiado mientras que el primero está sobreestadiado
OBJECTIVES: We intend to analyze the prognostic value of positive surgical margins depending on their number and location in pT2 patients. METHODS: We analyze 448 (34.3%) patients with positive surgical margins from a series of 1,310 T1-T2 patients treated with radical prostatectomy between 1989-2012. Of them 164 are pT2(+). 119 (72.6%) have unifocal affectation (41 (34.5%) unifocal in right lobe; 35 (29.4%) unifocal in left lobe, 40 (33.6%) unifocal in apex, 3 (2.5%) unifocal proximal) and 45 (27.4%) multifocal involvement. RESULTS: Unifocal and multifocal pT2(+) patients have not evidenced significant differences in any of the clinicopathologic variables compared. However the BPFS at 5 and 10 years is significantly worse in the multifocal group, (p<0.000). In the BPFS multivariate study of 164 pT2(+)influential variables are: multifocal involvement (HR: 3.4; 95%IC 1.7-6.9 p<0.000) and PSA (HR: 1.03; 95%IC 1.02-1.05 p<0.000), being PSA >15 ng/ml (HR: 3.7; 95%IC 2.1-6.6 p<0.000) the best cut-off point. Risk groups: Using the independent influence variables, the best model (using Cox models) includes two risk groups: Group 1 (0 variables): They are pT2(+) with unifocal affectation and PSA<15 ng/ml, (63%). Their BPFS are 81±4% and 77±4% (5 and 10 years). Grupo 2 (1-2 variables): They are pT2(+) with multifocal involvement, PSA>15 ng/ml or both of them, (37%). Their BPFS are 46±6% and 26±7% (5 and 10 years). The BPFS differs significantly between the two groups (p<0.000). The Group 1 BPFS is similar to the pT2(-) patients, (p:0.242). The Group 2 BPFS is similar to the pT3(+) patients, (p:0.637). The model explained significantly better the BPFS than any of the individual variables analyzed. CONCLUSIONS: In pT2(+) patients the prognosis is significantly worse in multifocal involvement. In addition two groups of patients can be clearly distinguished from the BPFS point view according to their influential variables. The data suggest that since the prognostic point view the second group is understaged while the first is overstaged
Asunto(s)
Humanos , Prostatectomía/métodos , Neoplasias de la Próstata/cirugía , Estadificación de Neoplasias , Supervivencia sin Enfermedad , Factores de Riesgo , Ajuste de Riesgo/métodosRESUMEN
OBJECTIVES: We intend to assess the prognostic influence of surgical margins on the biochemical progression free survival (BPFS) in patients classified as pT2 after radical prostatectomy. METHODS: We analyze a series of 1,132 T1-T2 patients with prostate cancer treated with radical prostatectomy between 1989-2009. PT3b, pT4 and patients with lymph node involvement were excluded from the series. The clinicopathologic variables and the BPFS of pT2(+), pT2(-) and pT3 patients are compared. The influential clinicopathologic variables in the BPFS are identified in the pT2(+) group and risk groups are designed. RESULTS: Of 1,051 patients evaluated finally: 598 (59,6) were pT2(-) 163 (15,5%) pT2(+)80 (7,6%) pT3a(-) and 210 (20%) pT3(+). Clinical characteristics of pT2(+). It is homogeneous with the pT2(-) group and significantly better than pT3(+) group in all the clinicopathologic variables evaluated. 5 and 10 year BPFS of the pT2(68 ± 3% and 57 ± 5%) is significantly worse than pT2( -)(87 ± 1% and 79 ± 2%), similar to pT3a(-) (75 ± 5% and 64 ± 7%and better than pT3(+) (44 ± 3% and (36 ± 3%) BPFS pT2(+) influential factors: Univariate study : Pathological Gleason score 7-10 (HR:2.1 95% IC: 1.1-4.1), (p=0.02)MRI that indicates T3 (HR:3.2 95%IC: 1.4-7.3), (p=0.04) PSA > 15 ng-ml (HR:4 95% IC: 2-8.2), (p < 0.0001) and high risk D'Amico group (HR:3.3 95%IC: 1.3-8.5), (p=0.01) are influential variables. A risk model with the involved variables can be designed. Each variable present is a point. Two groups are designed : Group 1 (0-1 variable) Group 2 (2-3 variables). 5 and 10 year BPFS for Group 1 are 71±5% and 69 ± 5%, and are 37 ± 12% and 22 ± 11% for Group 2. (p < 0.0001). CONCLUSIONS: Surgical margins in pT2 patients have independent influence in the BPFS. The group is heterogeneous and it can be divided into two risk groups accordingly to the BPFS influential variables: a larger group (86% pT2(+) with worse prognosis than pT2(-), and a smaller group (remaining 14%) with similar prognosis to pT3 (+).It is likely that pT2(+) patients are a mixture of understaged patients with others with iatrogenic margins or false margins due to poor assessment of the surgical specimen.
Asunto(s)
Prostatectomía , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Supervivencia sin Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Prostatectomía/métodos , Estudios RetrospectivosRESUMEN
OBJETIVO: Valorar en pacientes prostatectomizados y calificados como pT2, la influencia pronóstica sobre la Supervivencia Libre de Progresión Bioquímica (SLPB) de los márgenes afectados. MÉTODOS: Analizamos retrospectivamente una serie de 1.132 pacientes con cáncer de próstata T1-T2 tratados con prostatectomía radical entre 1.989-2.009. Se excluyen los pacientes con afectación de vesícula seminal, afectación ganglionar y pT4. Comparamos las variables clínico-patológicas y la SLPB de los pT2 (+) con pT2 (-) y pT3. Identificamos las variables clínico-patológicas influyentes en la SLPB de los pT2 (+) y con ellas diseñamos grupos de riesgo. RESULTADOS: De los 1.051 incluídos finalmente, 598 (59,6%) son pT2 (-); 163 (15,5%) pT2 (+); 80 (7,6%) pT3a (-) y 210 (20%) pT3 (+). Características clínicas de pT2 (+). Es homogéneo con el grupo pT2 (-) y significativamente mejor que los pT3(+) en todas las variables clínico-patológicas evaluadas. La (SLPB) de los pT2 (+) (68±3% y 57±5%) es significativamente peor que la de los pT2 (-) (87±1% y 79±2%), similar a los pT3a(-) (75±5% y 64±7%) y mejor que la de los pT3(+) (44±3% y 36±3%) en 5 y 10 años. Factores influyentes en SLPB en pT2 (+): Estudio univariado. Son influyentes: Gleason patológico 7-10 (HR:2,1; IC 95% 1,1-4,1), (p=0,02); RNM que indica T3 (HR:3,2; IC 95% 1,4-7,3), (p=0,04); PSA>15 ng/ml (HR:4; IC 95% 2-8,2), (p<0,0001) y DAmico alto riesgo (HR:3,3; IC 95% 1,3-8,5), (p=0,01). Se diseña un modelo de riesgo con las variables implicadas. Cada variable presente es un punto. Se diseñan dos grupos: Grupo 1 (86%)(0-1 variable); Grupo 2 (14%)(2-3 variables). La SLPB del grupo 1 es a 5 y 10 años de 71±5% y 69±5% y la del grupo 2 es de 37±12% y 22±11%.(p<0,0001). CONCLUSIONES: La afectación de márgenes en pacientes pT2 tiene una influencia independiente en la SLPB. El grupo es heterogéneo y puede ser dividido según las variables influyentes en la SLPB en un grupo mayor (86% de pT2 (+)) con peor pronóstico que los pT2 (-), y un grupo menor (14 % restante) con pronóstico similar a pT3 (+). Es probable que los pacientes pT2 (+) sean una mezcla de pacientes infraestadiados con otros con márgenes y atrogénicos o falsos por mala valoración de la pieza operatoria (AU)
OBJECTIVES: We intend to assess the prognostic influence of surgical margins on the biochemical progression free survival (BPFS) in patients classified as pT2 after radical prostatectomy. METHODS: We analyze a series of 1,132 T1-T2 patients with prostate cancer treated with radical prostatectomy between 1989-2009. PT3b, pT4 and patients with lymph node involvement were excluded from the series. The clinicopathologic variables and the BPFS of pT2 (+), pT2 (-) and pT3 patients are compared. The influential clinicopathologic variables in the BPFS are identified in the pT2 (+) group and risk groups are designed.RESULTS: Of 1,051 patients evaluated finally: 598 (59,6%) were pT2 (-); 163 (15,5%) pT2 (+);80 (7,6%) pT3a (-) and 210 (20%) pT 3(+).Clinical characteristics of pT2 (+). It is homogeneous with the pT2(-) group and significantly better than pT3 (+) group in all the clinicopathologic variables evaluated. 5 and 10 year BPFS of the pT2 (+) (68±3% and 57±5%) is significantly worse than pT2 (-) (87±1% and 79±2%), similar to pT3a (-) (75±5% and 64±7%) and better than pT3 (+) (44±3% and 36±3%).BPFS pT2 (+) influential factors: Univariate study: Pathological Gleason score 7-10 (HR:2.1; 95% IC: 1.1-4.1), (p=0.02); MRI that indicates T3 (HR:3.2; 95%IC: 1.4-7.3), (p=0.04); PSA>15 ng/ml (HR:4; 95%IC: 2-8.2), (p<0.0001) and high risk DAmico group (HR:3.3; 95%IC: 1.3-8.5), (p=0.01) are influential variables. A risk model with the involved variables can be designed. Each variable present is a point. Two groups are designed: Group 1 (0-1 variable); Group 2 (2-3 variables). 5 and 10 year BPFS for Group 1 are 71±5% and 69±5%, and are 37±12% and 22±11% for Group 2 (p <0.0001). CONCLUSIONS: Surgical margins in pT2 patients have independent influence in the BPFS. The group is heterogeneous and it can be divided into two risk groups accordingly to the BPFS influential variables: a larger group (86% pT2(+)) with worse prognosis than pT2(-), and a smaller group (remaining 14%) with similar prognosis to pT3 (+).It is likely that pT2(+) patients are a mixture of understaged patients with others with iatrogenic margins or false margins due to poor assessment of the surgical specimen (AU)
Asunto(s)
Humanos , Masculino , Prostatectomía/métodos , Neoplasias de la Próstata/cirugía , Neoplasia Residual/patología , Supervivencia sin Enfermedad , Factores de Riesgo , Estadificación de Neoplasias , Progresión de la EnfermedadRESUMEN
OBJECTIVES: Our aim is to design a predictive model of seminal vesicle involvement. using clinical data. METHODS: We studied 1128 patients with clinically localized adenocarcinoma treated by radical prostatectomy (127 were pT3b). We identified (logistic regression) clinical variables related with pT3b. With the multivariate study influential variables a seminal vesicle involvement risk model is designed. RESULTS: Seminal vesicle involvement related factors: In univariate study: the influential variables are: Gleason 7 (OR:2);Gleason 8-10 (OR:4.5) T2 (OR:2.6); bilateral involvement in biopsy (OR:3.1); PSA 10-20 ng/ml ( OR:3.3); PSA >20 ng/ ml (OR:9.5). In the multivariate study are influential: Gleason 7 (OR:1.56) Gleason 8-10 ( OR: 3.4); T2 (OR:1.9); PSA 10-20 ng/ml (OR:3.1) and PSA >20 ng/,ml (OR:8.8). Predictive model: using multivariate logistic regression the weight of each variable is valued and a value between 1 and 4 is given. Gleason 2-6, T1; PSA<10 ng/ml value 1; Gleason 7; T2 y PSA 10-20 ng/ml value 2; Gleason 8-10 and PSA >20 ng/ml value 4. Each patient has a marker that fluctuates between 3 and 10. 5 Groups are designed with significantly different risks (p<0.05 in all cases ): Group 1 (3 points) (OR:1) (risk: 2.4% 95%IC 0.7%-4.3%) Group 2 (4 points) (OR:2.7) (risk: 6.5% 95%IC 5%-7.9%); Group 3(5-6 points) (OR:7.1)( risk:15% 95%IC 11%-19%) Group 4 ( 7--8 points) (OR:33.4) (risk: 45.5%; 95%IC 30%-59%) Group 5 (9-10 points) (OR:57.3) (risk: 58.8% 95%IC 35%- 82%). CONCLUSION: The clinical model allows an accurate approximation to the seminal vesicles involvement risk.
Asunto(s)
Adenocarcinoma/patología , Neoplasias de la Próstata/patología , Vesículas Seminales/patología , Adenocarcinoma/cirugía , Adulto , Progresión de la Enfermedad , Humanos , Masculino , Valor Predictivo de las Pruebas , Prostatectomía , Neoplasias de la Próstata/cirugía , Medición de RiesgoRESUMEN
OBJETIVOS: Se pretende diseñar utilizando los datos clínicos un modelo predictivo de afectación de vesícula seminal. MÉTODOS: Se estudian 1.128 pacientes con adenocarcinoma clínicamente localizado tratados mediante prostatectomía radical (127 son pT3b). Se identifican (regresión logística) las variables clínicas relacionadas con pT3b. Con las variables del estudio multivariado se diseña un modelo de riesgo de afectación de vesícula seminal. RESULTADOS: Factores relacionados con afectación de vesícula seminal: En estudio univariado: las variables influyentes son: Gleason 7 (OR:2); Gleason 8-10 (OR:4,5); T2 (OR:2,6); afectación bilateral en biopsia (OR:3,1); PSA 10-20 ng/ml (OR:3,3); PSA >20 ng/ml (OR:9,5). En el estudio multivariado son influyentes: Gleason 7 (OR:1,56); Gleason 8-10 (OR: 3,4); T2 (OR:1,9); PSA 10-20 ng/ml (OR:3,1) y PSA >20 ng/ml (OR:8,8). MODELO PREDICTIVO: mediante regresión logística multivariante se valora el peso de cada variable y se da un valor entre 1 y 4. Gleason 2-6, T1; PSA<10 ng/ml valor 1; Gleason 7; T2 y PSA 10-20 ng/ml valor 2; Gleason 8-10 y PSA >20 ng/ml valor 4. Cada paciente tiene un marcador que oscila entre 3 y 10. Se diseñan 5 grupos con riesgos significativamente diferentes (p<0,05 en todos los casos): Grupo 1 (3 puntos)(OR:1)(riesgo: 2,4%; IC95% 0,7%-4,3%). Grupo 2 (4 puntos) (OR:2,7)(riesgo: 6,5%; IC95% 5%-7,9%). Grupo 3 (5-6 puntos)(OR:7,1) (riesgo:15%; IC95% 11%-19%). Grupo 4 (7-8 puntos)(OR:33,4)(riesgo: 45,5%; IC95% 30%-59%). Grupo 5 (9-10 puntos)(OR:57,3)(riesgo: 58,8%; IC95% 35%-82%). CONCLUSIÓN: El modelo clínico permite una aproximación precisa al riesgo de afectación de vesículas seminales (AU)
OBJECTIVES: Our aim is to design a predictive model of seminal vesicle involvement. using clinical data. METHODS: We studied 1128 patients with clinically localized adenocarcinoma treated by radical prostatectomy (127 were pT3b). We identified (logistic regression) clinical variables related with pT3b. With the multivariate study influential variables a seminal vesicle involvement risk model is designed. RESULTS: Seminal vesicle involvement related factors: In univariate study: the influential variables are: Gleason 7 (OR:2);Gleason 8-10 (OR:4.5); T2 (OR:2.6); bilateral involvement in biopsy (OR:3.1); PSA 10-20 ng/ml (OR:3.3); PSA >20 ng/ml (OR:9.5). In the multivariate study are influential: Gleason 7 (OR: 1.56); Gleason 8-10 (OR: 3.4); T2 (OR:1.9); PSA 10-20 ng/ml (OR:3.1) and PSA >20 ng/ml (OR:8.8). Predictive model: using multivariate logistic regression the weight of each variable is valued and a value between 1 and 4 is given. Gleason 2-6, T1; PSA<10 ng/ml value 1; Gleason 7; T2 y PSA 10-20 ng/ml value 2; Gleason 8-10 and PSA >20 ng/ml value 4. Each patient has a marker that fluctuates between 3 and 10. 5 Groups are designed with significantly different risks (p<0.05 in all cases): Group 1 (3 points) (OR:1)(risk: 2.4%; 95%IC 0.7%-4.3%) Group 2 (4 points) (OR:2.7)(risk: 6.5%; 95%IC 5%-7.9%) Group 3 (5-6 points) (OR:7.1)(risk:15%; 95%IC 11%-19%) Group 4 (7-8 points) (OR:33.4)(risk: 45.5%; 95%IC 30%-59%) Group 5 (9-10 points) (OR:57.3)(risk: 58.8%; 95%IC 35%-82%). CONCLUSION: The clinical model allows an accurate approximation to the seminal vesicles involvement risk (AU)
Asunto(s)
Humanos , Masculino , Neoplasias de la Próstata/complicaciones , Neoplasias de la Próstata/diagnóstico , Adenocarcinoma/complicaciones , Adenocarcinoma/diagnóstico , Vesículas Seminales/patología , Vesículas Seminales , Factores de Riesgo , Prostatectomía/métodos , Prostatectomía/estadística & datos numéricos , Modelos Logísticos , Análisis Multivariante , Biopsia/métodos , BiopsiaRESUMEN
We report the case of a 61-year-old man diagnosed in 2001 with rectal cancer (stage T3N1M0). The patient was treated with surgery, adjuvant chemotherapy and radiotherapy. In 2009, he was admitted to the urology department with a complaint of right hemiabdominal pain. The anatomopathological investigation reported renal metastasis of colon adenocarcinoma. After surgery, he received adjuvant chemotherapy. No tumour recurrence or metastasis was reported at the 22-month follow-up.